Atorvastatin API Market Research Report - Global Forecast till 2027

Global Atorvastatin API Market: Information by Application (Hypercholesterolemia, Hypertriglyceridemia, Dyslipidemia and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/6413-CR | May 2019 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Overview


The Global Atorvastatin API Market is expected to register a CAGR of 3.34% to reach USD 4,25,804.16 thousand by 2023.


Atorvastatin belongs to the group of medicines known as statins, also called as the HMG-CoA reductase inhibitors. HMG-CoA reductase is an enzyme involved in varying and maintaining the cholesterol levels in the body. Atorvastatin is mainly used to prevent vital cardiovascular occasions and lower total and bad cholesterol (LDL-cholesterol) and triglyceride levels in the blood.


The high adoption of atorvastatin in the treatment of cardiovascular diseases is expected to drive the market growth.  However, adverse health effects associated with atorvastatin are likely to restrain market growth.


Market Dynamics


The Global Atorvastatin API Market has been largely benefited by the rising adoption of atorvastatin in the treatment of cardiovascular diseases. Additionally, the growing prevalence of dyslipidemia in China provides opportunities for growth in the market. However, adverse health effects associated with atorvastatin is expected to restrain market growth.


Global Atorvastatin API Market Revenue, by Application, 2023 (USD Thousand)  Atorvastatin API Market_Image


Sources: MRFR Analysis


Segmentation


The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.


Key Players


The prominent players in the Global Atorvastatin API Market are Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India).


The players operating in the Global Atorvastatin API Market are focusing on product launches, along with expanding their global footprints by entering untapped markets.


Global Atorvastatin API Market Share, by Region, 2017 (%)  Atorvastatin API Market_Image                     


Sources: MRFR Analysis


Regional Analysis


North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023.  


The European market is estimated to exceed USD 1,31,094.04 thousand by 2023. High prevalence of hypercholesterolemia and mixed dyslipidemia are driving the growth of the Atorvastatin API market in the region. France is the major contributor to the growth of the regional market, followed by the UK.


Market Segmentation


Global Atorvastatin API Market, by Application



  • Hypercholesterolemia

  • Hypertriglyceridemia

  • Dyslipidemia

  • Others


Global Atorvastatin API Market, by Region



  • North America

    • US

    • Canada



  • Latin America



  • Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Eastern Europe

    • Rest of Europe





  • Asia-Pacific

    • China

    • India

    • Japan

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa 




Available Additional Customizations



  • Challenges in the market

  • Macroeconomic Indicators of the Global Atorvastatin API Market


Intended Audience



  • Atorvastatin API Manufacturers

  • Pharmaceutical Companies

  • Contract Research Organizations

  • Contract Manufacturing Organizations



Frequently Asked Questions (FAQ) :


atorvastatin API 425 million by 2023.

Atorvastatin API Market is expected to exhibit a strong 3.34% CAGR over the forecast period.

Atorvastatin is mainly used to lower LDL levels in the blood, thus averting major cardiovascular incidents.

High adoption of atorvastatin for the treatment of cardiovascular diseases is the major driver for the market.

North America dominated the global market in 2017 with a share of more than 40%.

1 Executive Summary

1.1 Market Attractiveness Analysis 14

1.1.1 Global Atorvastatin API Market, By Application 15

1.1.2 Global Atorvastatin API Market, By Region 16

2 Market Introduction

2.1 Definition 17

2.2 Scope of the Study 17

2.3 Market Structure 17

3 Research Methodology

3.1 Research Process 18

3.2 Primary Research 19

3.3 Secondary Research 20

3.4 Market Size Estimation 20

3.5 Forecast Model 21

3.6 List of Assumptions 22

4 Market Dynamics

4.1 Introduction 23

4.2 Drivers 24

4.2.1 High Adoption of Atorvastatin in the Treatment of Cardiovascular Diseases 24

4.2.2 Drivers Impact Analysis 24

4.3 Restraints 25

4.3.1 Adverse Health Effects Associated with Atorvastatin 25

4.3.2 Restraints Impact Analysis 25

4.4 Opportunities 26

4.4.1 Growing Prevalence of Dyslipidemia in China 26

5 Market Factor Analysis

5.1 Value Chain Analysis 27

5.1.1 Research and Development 27

5.1.2 Manufacturing 27

5.1.3 Distribution & Sale 28

5.1.4 Post-Sale Monitoring 28

5.2 Porter’s Five Forces Model 28

5.2.1 Threat of New Entrants 29

5.2.2 Intensity of Rivalry 29

5.2.3 Threat of Substitutes 29

5.2.4 Bargaining Power of Suppliers 29

5.2.5 Bargaining Power of Buyers 29

5.3 Regulatory Scenario 30

5.4 Pipeline Analysis 31

5.4.1 Introduction 31

5.4.2 Atorvastatin Calcium Tablets, 40 mg 31

5.4.3 Atorvastatin calcium 10 mg 31

5.4.4 Atorvastatin 32

5.5 Pricing Evolution 32

6 Atorvastatin API Market, by Application

6.1 Introduction 33

6.2 Hypercholesterolemia 35

6.3 Hypertriglyceridemia 36

6.4 Dyslipidemia 37

6.5 Others 38

7 Global Atorvastatin API Market, by Region

7.1 Introduction 39

7.2 North America 42

Atorvastatin API Market, by Application

7.2.1 U.S. 43

Atorvastatin API Market, by Application

7.2.2 Canada 44

Atorvastatin API Market, by Application

7.3 Latin America 45

Atorvastatin API Market, by Application

7.4 Europe 46

Atorvastatin API Market, by Application

7.4.1 Spain 47

Atorvastatin API Market, by Application

7.4.2 France 48

Atorvastatin API Market, by Application

7.4.3 UK 49

Atorvastatin API Market, by Application

7.4.4 Germany 50

Atorvastatin API Market, by Application

7.4.5 Italy 51

Atorvastatin API Market, by Application

7.4.6 Eastern Europe 52

Atorvastatin API Market, by Application

7.4.7 Rest of Europe 53

Atorvastatin API Market, by Application

7.5 Asia-Pacific 54

Atorvastatin API Market, by Application

7.5.1 China 55

Atorvastatin API Market, by Application

7.5.2 India 56

Atorvastatin API Market, by Application

7.5.3 Japan 57

Atorvastatin API Market, by Application

7.5.4 Rest of Asia-Pacific 58

Atorvastatin API Market, by Application

7.6 The Middle East and Africa 59

Atorvastatin API Market, by Application

7.6.1 Middle East 60

Atorvastatin API Market, by Application

7.6.2 Africa 61

Atorvastatin API Market, by Application

8 Competitive Landscape

8.1 Competitive Landscape 63

8.1.1 Introduction 63

8.1.2 Key Development Analysis 64

8.1.3 Market Strategy Analysis 64

9 Company Profiles

9.1 Pfizer Inc 65

9.1.1 Financial Overview 65

9.1.2 Products/Services Offered 66

9.1.3 Key Developments 66

9.1.4 SWOT Analysis 66

9.1.5 Key Strategies 66

9.2 Dr. Reddy’s Laboratories Ltd 67

9.2.1 Financial Overview 67

9.2.2 Products/Services Offered 68

9.2.3 Key Developments 68

9.2.4 SWOT Analysis 68

9.2.5 Key Strategies 68

9.3 Sun Pharmaceutical Industries Ltd 69

9.3.1 Financial Overview 69

9.3.2 Products/Services Offered 70

9.3.3 Key Developments 70

9.3.4 SWOT Analysis 70

9.3.5 Key Strategies 70

9.4 Mylan N.V. 71

9.4.1 Financial Overview 71

9.4.2 Products/Services Offered 72

9.4.3 Key Developments 72

9.4.4 SWOT Analysis 72

9.4.5 Key Strategies 72

9.5 Cipla Inc 73

9.5.1 Financial Overview 73

9.5.2 Products/Services Offered 74

9.5.3 Key Developments 74

9.5.4 SWOT Analysis 75

9.5.5 Key Strategies 75

9.6 Zydus Pharmaceuticals, Inc 76

9.6.1 Financial Overview 76

9.6.2 Products/Services Offered 77

9.6.3 Key Developments 77

9.6.4 SWOT Analysis 77

9.6.5 Key Strategies 77

9.7 Apotex Inc 78

9.7.1 Financial Overview 78

9.7.2 Products/Services Offered 78

9.7.3 Key Developments 78

9.7.4 SWOT Analysis 79

9.7.5 Key Strategies 79

9.8 Akron Pharma Inc. 80

9.8.1 Financial Overview 80

9.8.2 Products/Services Offered 80

9.8.3 Key Developments 80

9.8.4 SWOT Analysis 80

9.8.5 Key Strategies 80

9.9 Accord-UK Ltd 81

9.9.1 Financial Overview 81

9.9.2 Products/Services Offered 81

9.9.3 Key Developments 81

9.9.4 SWOT Analysis 82

9.9.5 Key Strategies 82

9.10 Sanis 83

9.10.1 Financial Overview 83

9.10.2 Products/Services Offered 83

9.10.3 Key Developments 83

9.10.4 SWOT Analysis 84

9.10.5 Key Strategies 84

10 Conclusion

11 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 22

TABLE 2 ATORVASTATIN API MARKET: PIPELINE ANALYSIS 31

TABLE 3 PRICING EVOLUTION (2020–2020), BY REGION (USD PER KG) 32

TABLE 4 GLOBAL ATORVASTATIN API, BY APPLICATION, 2020–2027 (USD MILLION) 33

TABLE 5 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 34

TABLE 6 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 7 GLOBAL ATORVASTATIN API MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2020–2027 (KILO TONS) 35

TABLE 8 GLOBAL ATORVASTATIN APIMARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 9 GLOBAL ATORVASTATIN API MARKET FOR HYPERTRIGLYCERIDEMIA, BY REGION, 2020–2027 (KILO TONS) 36

TABLE 10 GLOBAL ATORVASTATIN API MARKET FOR DYSLIPIDEMIA, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 11 GLOBAL ATORVASTATIN APIMARKET FOR DYSLIPIDEMIA, BY REGION, 2020–2027 (KILO TONS) 37

TABLE 12 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 13 GLOBAL ATORVASTATIN API MARKET FOR OTHERS, BY REGION, 2020–2027 (KILO TONS) 38

TABLE 14 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 15 GLOBAL ATORVASTATIN API MARKET, BY REGION, 2020–2027 (KILO TONS) 41

TABLE 16 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 41

TABLE 17 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 41

TABLE 18 NORTH AMERICA ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 42

TABLE 19 NORTH AMERICA ATORVASTATIN APIMARKET, BY COUNTRY, 2020–2027 (KILO TONS) 42

TABLE 20 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 42

TABLE 21 NORTH AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 43

TABLE 22 U.S. ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 43

TABLE 23 U.S. ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 44

TABLE 24 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 44

TABLE 25 CANADA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 44

TABLE 26 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 45

TABLE 27 LATIN AMERICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 45

TABLE 28 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 46

TABLE 29 EUROPE ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (KILO TONS) 46

TABLE 30 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 47

TABLE 31 EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 47

TABLE 32 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 47

TABLE 33 SPAIN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 48

TABLE 34 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 48

TABLE 35 FRANCE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 49

TABLE 36 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 49

TABLE 37 UK ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 49

TABLE 38 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 50

TABLE 39 GERMANY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 50

TABLE 40 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 51

TABLE 41 ITALY ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 51

TABLE 42 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 52

TABLE 43 EASTERN EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 52

TABLE 44 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 53

TABLE 45 REST OF EUROPE ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 53

TABLE 46 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

TABLE 47 ASIA-PACIFIC ATORVASTATIN API MARKET, BY COUNTRY, 2020–2027 (KILO TONS) 54

TABLE 48 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 54

TABLE 49 ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 55

TABLE 50 CHINA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 55

TABLE 51 CHINA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 56

TABLE 52 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 56

TABLE 53 INDIA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 56

TABLE 54 JAPAN ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 57

TABLE 55 JAPAN ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 57

TABLE 56 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 58

TABLE 57 REST OF ASIA-PACIFIC ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 58

TABLE 58 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2020–2027 (USD MILLION) 59

TABLE 59 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY REGION, 2020–2027 (KILO TONS) 59

TABLE 60 THE MIDDLE EAST AND AFRICA ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 59

TABLE 61 THE MIDDLE EAST AND AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 60

TABLE 62 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 60

TABLE 63 MIDDLE EAST ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 61

TABLE 64 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (USD MILLION) 61

TABLE 65 AFRICA ATORVASTATIN APIMARKET, BY APPLICATION, 2020–2027 (KILO TONS) 62

12 List of Figures

FIGURE 1 MARKET SYNOPSIS 13

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ATORVASTATIN API MARKET 14

FIGURE 3 GLOBAL ATORVASTATIN API MARKET ANALYSIS, BY APPLICATION 15

FIGURE 4 GLOBAL ATORVASTATIN API MARKET ANALYSIS BY REGION 16

FIGURE 5 GLOBAL ATORVASTATIN API MARKET: MARKET STRUCTURE 17

FIGURE 6 RESEARCH PROCESS OF MRFR 18

FIGURE 7 TOP-DOWN & BOTTOM-UP APPROACH 21

FIGURE 8 MARKET DYNAMICS OVERVIEW 23

FIGURE 9 DRIVERS IMPACT ANALYSIS 24

FIGURE 10 RESTRAINTS IMPACT ANALYSIS 25

FIGURE 11 SUPPLY CHAIN: GLOBAL ATORVASTATIN API MARKET 27

FIGURE 12 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL ATORVASTATIN API MARKET 28

FIGURE 13 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 33

FIGURE 14 GLOBAL ATORVASTATIN API MARKET, BY APPLICATION, 2020–2027 (KILO TONS) 34

FIGURE 15 GLOBAL ATORVASTATIN API MARKET BY REGION, 2020 (VALUE %) 39

FIGURE 16 GLOBAL ATORVASTATIN API MARKET BY REGION, 2020–2027 (KILO TONS) 40



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.